Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 144

1.

The activity of the Striatal-enriched protein tyrosine phosphatase in neuronal cells is modulated by adenosine A2A receptor.

Mallozzi C, Pepponi R, Visentin S, Chiodi V, Lombroso PJ, Bader M, Popoli P, Domenici MR.

J Neurochem. 2020 Feb;152(3):284-298. doi: 10.1111/jnc.14866. Epub 2019 Oct 10.

PMID:
31520531
2.

Adenosine A2A receptor stimulation restores cell functions and differentiation in Niemann-Pick type C-like oligodendrocytes.

De Nuccio C, Bernardo A, Ferrante A, Pepponi R, Martire A, Falchi M, Visentin S, Popoli P, Minghetti L.

Sci Rep. 2019 Jul 5;9(1):9782. doi: 10.1038/s41598-019-46268-8.

3.

Adenosine A2A receptor as potential therapeutic target in neuropsychiatric disorders.

Domenici MR, Ferrante A, Martire A, Chiodi V, Pepponi R, Tebano MT, Popoli P.

Pharmacol Res. 2019 Sep;147:104338. doi: 10.1016/j.phrs.2019.104338. Epub 2019 Jul 2. Review.

PMID:
31276772
4.

Modulating P1 Adenosine Receptors in Disease Progression of SOD1G93A Mutant Mice.

Armida M, Matteucci A, Pèzzola A, Baqi Y, Müller CE, Popoli P, Potenza RL.

Neurochem Res. 2019 May;44(5):1037-1042. doi: 10.1007/s11064-019-02745-0. Epub 2019 Feb 12.

PMID:
30756215
5.

Neuroprotective potential of adenosine A1 receptor partial agonists in experimental models of cerebral ischemia.

Martire A, Lambertucci C, Pepponi R, Ferrante A, Benati N, Buccioni M, Dal Ben D, Marucci G, Klotz KN, Volpini R, Popoli P.

J Neurochem. 2019 Apr;149(2):211-230. doi: 10.1111/jnc.14660. Epub 2019 Feb 11.

6.

The Role of Adenosine Tone and Adenosine Receptors in Huntington's Disease.

Blum D, Chern Y, Domenici MR, Buée L, Lin CY, Rea W, Ferré S, Popoli P.

J Caffeine Adenosine Res. 2018 Jun 1;8(2):43-58. doi: 10.1089/caff.2018.0006. Review.

7.

Neuronal adenosine A2A receptor overexpression is neuroprotective towards 3-nitropropionic acid-induced striatal toxicity: a rat model of Huntington's disease.

Domenici MR, Chiodi V, Averna M, Armida M, Pèzzola A, Pepponi R, Ferrante A, Bader M, Fuxe K, Popoli P.

Purinergic Signal. 2018 Sep;14(3):235-243. doi: 10.1007/s11302-018-9609-4. Epub 2018 May 16.

8.

The adenosine A2A receptor agonist T1-11 ameliorates neurovisceral symptoms and extends the lifespan of a mouse model of Niemann-Pick type C disease.

Ferrante A, Pezzola A, Matteucci A, Di Biase A, Attorri L, Armida M, Martire A, Chern Y, Popoli P.

Neurobiol Dis. 2018 Feb;110:1-11. doi: 10.1016/j.nbd.2017.10.013. Epub 2017 Oct 25.

PMID:
29079454
9.

Regenerative medicine in Huntington's disease: Strengths and weaknesses of preclinical studies.

Tartaglione AM, Popoli P, Calamandrei G.

Neurosci Biobehav Rev. 2017 Jun;77:32-47. doi: 10.1016/j.neubiorev.2017.02.017. Epub 2017 Feb 20. Review.

PMID:
28223129
10.

Fingolimod: A Disease-Modifier Drug in a Mouse Model of Amyotrophic Lateral Sclerosis.

Potenza RL, De Simone R, Armida M, Mazziotti V, Pèzzola A, Popoli P, Minghetti L.

Neurotherapeutics. 2016 Oct;13(4):918-927. doi: 10.1007/s13311-016-0462-2.

11.

Aberrant self-grooming as early marker of motor dysfunction in a rat model of Huntington's disease.

Tartaglione AM, Armida M, Potenza RL, Pezzola A, Popoli P, Calamandrei G.

Behav Brain Res. 2016 Oct 15;313:53-57. doi: 10.1016/j.bbr.2016.06.058. Epub 2016 Jun 30.

PMID:
27374158
12.

Stimulation of adenosine A2A receptors reduces intracellular cholesterol accumulation and rescues mitochondrial abnormalities in human neural cell models of Niemann-Pick C1.

Ferrante A, De Nuccio C, Pepponi R, Visentin S, Martire A, Bernardo A, Minghetti L, Popoli P.

Neuropharmacology. 2016 Apr;103:155-62. doi: 10.1016/j.neuropharm.2015.11.022. Epub 2015 Nov 26.

PMID:
26631535
13.

Striatal adenosine-cannabinoid receptor interactions in rats over-expressing adenosine A2A receptors.

Chiodi V, Ferrante A, Ferraro L, Potenza RL, Armida M, Beggiato S, Pèzzola A, Bader M, Fuxe K, Popoli P, Domenici MR.

J Neurochem. 2016 Mar;136(5):907-17. doi: 10.1111/jnc.13421. Epub 2015 Nov 24.

14.

Expression, pharmacology and functional activity of adenosine A1 receptors in genetic models of Huntington's disease.

Ferrante A, Martire A, Pepponi R, Varani K, Vincenzi F, Ferraro L, Beggiato S, Tebano MT, Popoli P.

Neurobiol Dis. 2014 Nov;71:193-204. doi: 10.1016/j.nbd.2014.08.013. Epub 2014 Aug 15.

PMID:
25132555
15.

Spinal cord pathology is ameliorated by P2X7 antagonism in a SOD1-mutant mouse model of amyotrophic lateral sclerosis.

Apolloni S, Amadio S, Parisi C, Matteucci A, Potenza RL, Armida M, Popoli P, D'Ambrosi N, Volonté C.

Dis Model Mech. 2014 Sep;7(9):1101-9. doi: 10.1242/dmm.017038. Epub 2014 Jul 18.

16.

The stimulation of adenosine A2A receptors ameliorates the pathological phenotype of fibroblasts from Niemann-Pick type C patients.

Visentin S, De Nuccio C, Bernardo A, Pepponi R, Ferrante A, Minghetti L, Popoli P.

J Neurosci. 2013 Sep 25;33(39):15388-93. doi: 10.1523/JNEUROSCI.0558-13.2013.

17.

Cocaine-induced changes of synaptic transmission in the striatum are modulated by adenosine A2A receptors and involve the tyrosine phosphatase STEP.

Chiodi V, Mallozzi C, Ferrante A, Chen JF, Lombroso PJ, Di Stasi AM, Popoli P, Domenici MR.

Neuropsychopharmacology. 2014 Feb;39(3):569-78. doi: 10.1038/npp.2013.229. Epub 2013 Aug 30.

18.

A2A adenosine receptors are up-regulated in lymphocytes from amyotrophic lateral sclerosis patients.

Vincenzi F, Corciulo C, Targa M, Casetta I, Gentile M, Granieri E, Borea PA, Popoli P, Varani K.

Amyotroph Lateral Scler Frontotemporal Degener. 2013 Sep;14(5-6):406-13. doi: 10.3109/21678421.2013.793358. Epub 2013 May 16.

PMID:
23679925
19.

Prolonged lifespan with enhanced exploratory behavior in mice overexpressing the oxidized nucleoside triphosphatase hMTH1.

De Luca G, Ventura I, Sanghez V, Russo MT, Ajmone-Cat MA, Cacci E, Martire A, Popoli P, Falcone G, Michelini F, Crescenzi M, Degan P, Minghetti L, Bignami M, Calamandrei G.

Aging Cell. 2013 Aug;12(4):695-705. doi: 10.1111/acel.12094. Epub 2013 May 30.

20.

BDNF prevents NMDA-induced toxicity in models of Huntington's disease: the effects are genotype specific and adenosine A2A receptor is involved.

Martire A, Pepponi R, Domenici MR, Ferrante A, Chiodi V, Popoli P.

J Neurochem. 2013 Apr;125(2):225-35. doi: 10.1111/jnc.12177. Epub 2013 Feb 27.

21.

Effects of chronic caffeine intake in a mouse model of amyotrophic lateral sclerosis.

Potenza RL, Armida M, Ferrante A, Pèzzola A, Matteucci A, Puopolo M, Popoli P.

J Neurosci Res. 2013 Apr;91(4):585-92. doi: 10.1002/jnr.23185. Epub 2013 Jan 30.

PMID:
23361938
22.

NMDA receptor dysfunction contributes to impaired brain-derived neurotrophic factor-induced facilitation of hippocampal synaptic transmission in a Tau transgenic model.

Burnouf S, Martire A, Derisbourg M, Laurent C, Belarbi K, Leboucher A, Fernandez-Gomez FJ, Troquier L, Eddarkaoui S, Grosjean ME, Demeyer D, Muhr-Tailleux A, Buisson A, Sergeant N, Hamdane M, Humez S, Popoli P, Buée L, Blum D.

Aging Cell. 2013 Feb;12(1):11-23. doi: 10.1111/acel.12018. Epub 2012 Nov 23.

23.

Potential therapeutic relevance of adenosine A2B and A2A receptors in the central nervous system.

Popoli P, Pepponi R.

CNS Neurol Disord Drug Targets. 2012 Sep;11(6):664-74. Review.

PMID:
22963436
24.

Adenosine A(2A)-cannabinoid CB(1) receptor interaction: an integrative mechanism in striatal glutamatergic neurotransmission.

Tebano MT, Martire A, Popoli P.

Brain Res. 2012 Oct 2;1476:108-18. doi: 10.1016/j.brainres.2012.04.051. Epub 2012 May 4. Review.

PMID:
22565012
25.

Unbalance of CB1 receptors expressed in GABAergic and glutamatergic neurons in a transgenic mouse model of Huntington's disease.

Chiodi V, Uchigashima M, Beggiato S, Ferrante A, Armida M, Martire A, Potenza RL, Ferraro L, Tanganelli S, Watanabe M, Domenici MR, Popoli P.

Neurobiol Dis. 2012 Mar;45(3):983-91. doi: 10.1016/j.nbd.2011.12.017. Epub 2011 Dec 23.

PMID:
22207189
26.

Altered oxidative stress profile in the cortex of mice fed an enriched branched-chain amino acids diet: possible link with amyotrophic lateral sclerosis?

Piscopo P, Crestini A, Adduci A, Ferrante A, Massari M, Popoli P, Vanacore N, Confaloni A.

J Neurosci Res. 2011 Aug;89(8):1276-83. doi: 10.1002/jnr.22655. Epub 2011 May 2.

PMID:
21538464
27.

Complex behavioral and synaptic effects of dietary branched chain amino acids in a mouse model of amyotrophic lateral sclerosis.

Venerosi A, Martire A, Rungi A, Pieri M, Ferrante A, Zona C, Popoli P, Calamandrei G.

Mol Nutr Food Res. 2011 Apr;55(4):541-52. doi: 10.1002/mnfr.201000296. Epub 2011 Jan 5.

PMID:
21462321
28.

The role of the Istituto Superiore di Sanità as the competent authority for Phase I trials in the translation of advanced therapies.

Popoli P, Cometa MF, Fabi F, Meneguz A.

Ann Ist Super Sanita. 2011;47(1):79-82. doi: 10.4415/ANN_11_01_16. Review.

29.

New challenges in translational medicine: transforming the advancement of science into cures. Preface.

Garaci E, Popoli P.

Ann Ist Super Sanita. 2011;47(1):5-7. doi: 10.4415/ANN_11_01_02. No abstract available.

30.

Pre-synaptic adenosine A2A receptors control cannabinoid CB1 receptor-mediated inhibition of striatal glutamatergic neurotransmission.

Martire A, Tebano MT, Chiodi V, Ferreira SG, Cunha RA, Köfalvi A, Popoli P.

J Neurochem. 2011 Jan;116(2):273-80. doi: 10.1111/j.1471-4159.2010.07101.x. Epub 2010 Dec 2.

31.

Role of adenosine A(2A) receptors in modulating synaptic functions and brain levels of BDNF: a possible key mechanism in the pathophysiology of Huntington's disease.

Tebano MT, Martire A, Chiodi V, Ferrante A, Popoli P.

ScientificWorldJournal. 2010 Sep 1;10:1768-82. doi: 10.1100/tsw.2010.164. Review.

32.

Three years of experience: the Italian registry and safety data update.

Mancardi GL, Tedeschi G, Amato MP, D'Alessandro R, Drago F, Milanese C, Popoli P, Rossi P, Savettieri G, Tola MR, Comi G, Pozzilli C, Bertolotto A, Marrosu MG, Grimaldi LM, Laroni A, Vanacore N, Covezzoli A, De Rosa M, Piccinni C, Montanaro N, Periotto L, Iommelli R, Tomino C, Provinciali L.

Neurol Sci. 2011 Jan;31 Suppl 3:295-7. doi: 10.1007/s10072-010-0356-8.

PMID:
20644975
33.

Influence of CGS 21680, a selective adenosine A(2A) receptor agonist, on NMDA receptor function and expression in the brain of Huntington's disease mice.

Ferrante A, Martire A, Armida M, Chiodi V, Pézzola A, Potenza RL, Domenici MR, Popoli P.

Brain Res. 2010 Apr 6;1323:184-91. doi: 10.1016/j.brainres.2010.01.080. Epub 2010 Feb 4.

PMID:
20138162
34.

Striatal 6-OHDA lesion in mice: Investigating early neurochemical changes underlying Parkinson's disease.

Branchi I, D'Andrea I, Armida M, Carnevale D, Ajmone-Cat MA, Pèzzola A, Potenza RL, Morgese MG, Cassano T, Minghetti L, Popoli P, Alleva E.

Behav Brain Res. 2010 Mar 17;208(1):137-43. doi: 10.1016/j.bbr.2009.11.020. Epub 2009 Nov 13.

PMID:
19914295
35.

The pharmacovigilance program on natalizumab in Italy: 2 years of experience.

Tedeschi G, Amato MP, D'Alessandro R, Drago F, Milanese C, Popoli P, Rossi P, Savettieri G, Tola MR, Vanacore N, Covezzoli A, De Rosa M, Comi G, Pozzilli C, Bertolotto A, Marrosu MG, Grimaldi LM, Piccinni C, Montanaro N, Periotto L, Iommelli R, Addis A, Martini N, Provinciali L, Mancardi GL.

Neurol Sci. 2009 Oct;30 Suppl 2:S163-5. doi: 10.1007/s10072-009-0143-6.

PMID:
19882367
36.

Remodeling of striatal NMDA receptors by chronic A(2A) receptor blockade in Huntington's disease mice.

Martire A, Ferrante A, Potenza RL, Armida M, Ferretti R, Pézzola A, Domenici MR, Popoli P.

Neurobiol Dis. 2010 Jan;37(1):99-105. doi: 10.1016/j.nbd.2009.09.012. Epub 2009 Oct 3.

PMID:
19804830
37.

Adenosine A2A receptors enable the synaptic effects of cannabinoid CB1 receptors in the rodent striatum.

Tebano MT, Martire A, Chiodi V, Pepponi R, Ferrante A, Domenici MR, Frank C, Chen JF, Ledent C, Popoli P.

J Neurochem. 2009 Sep;110(6):1921-30. doi: 10.1111/j.1471-4159.2009.06282.x. Epub 2009 Jul 17.

38.

Region-specific neuroprotective effect of ZM 241385 towards glutamate uptake inhibition in cultured neurons.

Pepponi R, Ferrante A, Ferretti R, Martire A, Popoli P.

Eur J Pharmacol. 2009 Sep 1;617(1-3):28-32. doi: 10.1016/j.ejphar.2009.07.016. Epub 2009 Jul 18.

PMID:
19619523
39.

A role for oxidized DNA precursors in Huntington's disease-like striatal neurodegeneration.

De Luca G, Russo MT, Degan P, Tiveron C, Zijno A, Meccia E, Ventura I, Mattei E, Nakabeppu Y, Crescenzi M, Pepponi R, Pèzzola A, Popoli P, Bignami M.

PLoS Genet. 2008 Nov;4(11):e1000266. doi: 10.1371/journal.pgen.1000266. Epub 2008 Nov 21.

40.

Natalizumab: a country-based surveillance program.

Mancardi GL, Amato MP, D'Alessandro R, Drago F, Milanese C, Popoli P, Provinciali L, Rossi P, Savettieri G, Tedeschi G, Tola MR, Vanacore N, Covezzoli A, De Rosa M, Piccinni C, Montanaro N, Periotto L, Addis A, Martini N.

Neurol Sci. 2008 Sep;29 Suppl 2:S235-7. doi: 10.1007/s10072-008-0948-8.

PMID:
18690503
41.

A critical evaluation of adenosine A2A receptors as potentially "druggable" targets in Huntington's disease.

Popoli P, Blum D, Domenici MR, Burnouf S, Chern Y.

Curr Pharm Des. 2008;14(15):1500-11. Review.

PMID:
18537673
42.

An update on adenosine A2A-dopamine D2 receptor interactions: implications for the function of G protein-coupled receptors.

Ferré S, Quiroz C, Woods AS, Cunha R, Popoli P, Ciruela F, Lluis C, Franco R, Azdad K, Schiffmann SN.

Curr Pharm Des. 2008;14(15):1468-74. Review.

43.

Regulation of brain functions by A2A receptors: implication for therapeutics.

Popoli P.

Curr Pharm Des. 2008;14(15):1466-7. No abstract available.

PMID:
18537669
44.

Is the functional interaction between adenosine A(2A) receptors and metabotropic glutamate 5 receptors a general mechanism in the brain? Differences and similarities between the striatum and the hippocampus.

Tebano MT, Martire A, Pepponi R, Domenici MR, Popoli P.

Purinergic Signal. 2006 Nov;2(4):619-25. doi: 10.1007/s11302-006-9026-y. Epub 2006 Sep 28.

45.

Adenosine A(2A) receptors modulate BDNF both in normal conditions and in experimental models of Huntington's disease.

Potenza RL, Tebano MT, Martire A, Domenici MR, Pepponi R, Armida M, Pèzzola A, Minghetti L, Popoli P.

Purinergic Signal. 2007 Sep;3(4):333-8. doi: 10.1007/s11302-007-9066-y. Epub 2007 Sep 15.

46.

Nonmotor symptoms in Parkinson's disease: investigating early-phase onset of behavioral dysfunction in the 6-hydroxydopamine-lesioned rat model.

Branchi I, D'Andrea I, Armida M, Cassano T, Pèzzola A, Potenza RL, Morgese MG, Popoli P, Alleva E.

J Neurosci Res. 2008 Jul;86(9):2050-61. doi: 10.1002/jnr.21642.

PMID:
18335518
47.

Quinolinic acid induced neurodegeneration in the striatum: a combined in vivo and in vitro analysis of receptor changes and microglia activation.

Moresco RM, Lavazza T, Belloli S, Lecchi M, Pezzola A, Todde S, Matarrese M, Carpinelli A, Turolla E, Zimarino V, Popoli P, Malgaroli A, Fazio F.

Eur J Nucl Med Mol Imaging. 2008 Apr;35(4):704-15. Epub 2007 Dec 15.

PMID:
18080815
48.

Behavioural and neurochemical characterization of the adenosine A2A receptor antagonist ST1535.

Galluzzo M, Pintor A, Pèzzola A, Grieco R, Borsini F, Popoli P.

Eur J Pharmacol. 2008 Jan 28;579(1-3):149-52. Epub 2007 Oct 30.

PMID:
18036583
49.

Adenosine A2A receptors and brain injury: broad spectrum of neuroprotection, multifaceted actions and "fine tuning" modulation.

Chen JF, Sonsalla PK, Pedata F, Melani A, Domenici MR, Popoli P, Geiger J, Lopes LV, de Mendonça A.

Prog Neurobiol. 2007 Dec;83(5):310-31. Epub 2007 Sep 29. Review.

PMID:
18023959
50.

Adenosine A(2A) receptors are required for normal BDNF levels and BDNF-induced potentiation of synaptic transmission in the mouse hippocampus.

Tebano MT, Martire A, Potenza RL, Grò C, Pepponi R, Armida M, Domenici MR, Schwarzschild MA, Chen JF, Popoli P.

J Neurochem. 2008 Jan;104(1):279-86. Epub 2007 Nov 14.

Supplemental Content

Loading ...
Support Center